KHA has been a forerunner in the education of thousands internationally about building immunity, especially when it comes to HIV and AIDS. They publish Positive Health News, and I placed an excerpt here about lauric acid which they published in 1997.
It seems to have taken a heck of a long time for mainstream medicine to catch on.
MARY ENIG Ph.D. ON NATURAL COCONUT OIL FOR AIDS and OTHER VIRAL INFECTIONS On July 19, 1995, Enig was quoted in an article published in The HINDU, India’s National Newspaper as stating that coconut oil is converted by the body into “Monolaurin” a fatty acid with anti-viral properties that might be useful in the treatment of AIDS. The staff reporter for The HINDU wrote about Enig’s presentation at a press conference in Kochi and wrote the following:
“There was an instance in the US in which an infant tested HIV positive had become HIV negative. That it was fed with an infant formula with a high coconut oil content gains significance in this context and at present an effort was on to find out how the “viral load” of an HIV infected baby came down when fed a diet that helped in the generation of Monolaurin in the body.”
The reporter commented on Enig’s observations that “Monolaurin helped in inactivating other viruses such as measles, herpes, vesicular stomatitis and Cytomegalovirus (CMV) and that research undertaken so far on coconut oil also indicated that it offered a certain measure of protection against cancer-inducing substances. "
In another article published in the Indian Coconut Journal, Sept., 1995, Dr. Enig stated:
“Recognition of the antimicrobial activity of the monoglyceride of lauric acid (Monolaurin) has been reported since 1966. The seminal work can be credited to Jon Kabara. This early research was directed at the virucidal effects because of possible problems related to food preservation. Some of the early work by Hierholzer and Kabara (1982) that showed virucidal effects of Monolaurin on enveloped RNA and DNA viruses was done in conjunction with the Center for Disease Control of the US Public Health Service with selected prototypes or recognized strains of enveloped viruses. The envelope of these viruses is a lipid membrane.”
Enig stated in her article that Monolaurin, of which the precursor is lauric acid, disrupted the lipid membranes of envelope viruses and also inactivated bacteria, yeast and fungi. She wrote:“Of the saturated fatty acids, lauric acid has greater antiviral activity than either caprylic acid (C-10) or myristic acid (C-14). The action attributed to Monolaurin is that of solubilizing the lipids ..in the envelope of the virus causing the disintegration of the virus envelope.” In India, coconut oil is fed to calves to treat Cryptosporidium as reported by Lark Lands Ph.D. in her upcoming book “Positively Well” (1).
While HHV-6A was not mentioned by Enig, HHV-6A is an enveloped virus and would be expected to disintegrate in the presence of lauric acid and/or Monolaurin. Some of the pathogens reported by Enig to be inactivated by Monolaurin include HIV, measles, vercular stomatitis virus (VSV), herpes simplex virus (HSV-1), visna, cytomegalovirus (CMV), Influenza virus, Pneumonovirus, Syncytial virus and Rubeola. Some bacteria inactivated by Monolaurin include listeria, Staphylococcus aureus, Streptococcus agalactiae, Groups A, B, F and G streptococci, Gram-positive organisms; and gram-negative organisms, if treated with chelator.
Enig reported that only one infant formula “Impact” contains lauric acid while the more widely promoted formulas like “Ensure” do not contain lauric acid and often contain some hydrogenated fats (trans fatty acids). A modified ester of lauric acid, Monolaurin (available in capsules), is sold in health food stores and is manufactured by Ecological Formulas, Concord, CA.
ENIG ON A THERAPEUTIC DOSE
Based on her calculations on the amount of lauric acid found in human Mother’s milk, Dr. Enig suggests a rich lauric acid diet would contain about 24 grams of lauric acid daily for the average adult. This amount could be found in about 3.5 tablespoons of coconut oil or 10 ounces of “Pure Coconut Milk.” Coconut Milk is made in Sri Lanka and imported into the United States. It can be found in health food stores and in local grocery stores in the International Foods section or in specialty grocery stores that sell products imported from Thailand, the Philippines or East India. About 7 ounces of raw coconut daily would contain 24 grams of lauric acid. 24 grams of lauric acid is the therapeutic daily dose for adults suggested by Mary Enig based on her research of the lauric acid content of mother’s milk. (1)
1. Positively Well, by Lark Lands Ph.D. Her new book discusses lauric acid and suggests many treatment options for persons with AIDS or CFIDS and may be ordered by calling 905-672-7470 or 800-542-8102
SCIENTIFIC RESEARCH ON THE ANTI-VIRAL EFFECTS OF LAURIC ACID
Mary Enig cites 24 references in her 7 page article on “Lauric Acid for HIV-infected Individuals,” a few of which are as follows:
1. Issacs, C.E. et al. Inactivation of enveloped viruses in human bodily fluids by purified lipids. Annals of the New York Academy of Sciences 1994;724:457-464.
2. Kabara, J.J. Antimicrobial agents derived from fatty acids. Journal of the American Oil Chemists Society 1984;61:397-403.
3. Hierholzer, J.C. and Kabara J.J. In vitro effects on Monolaurin compounds on enveloped RNA and DNA viruses. Journal of Food Safety 1982;4:1-12.
4. Wang, L.L. and Johnson, E.A. Inhibition of Listeria monocytogenes by fatty acids and monoglycerides. Appli Environ Microbiol 1992; 58:624-629.
5. Issacs, C.E. et al. Membrane-disruptive effect of human milk: inactivation of enveloped viruses. Journal of Infectious Diseases 1986;154:966-971.
6. Anti-viral effects of monolaruin. JAQA 1987;2:4-6 7. Issacs C.E. et al. Antiviral and antibacterial lipids in human milk and infant formula feeds. Archives of Disease in Childhood 1990;65:861-864.
Note: Enig’s article in the Indian Coconut Journal has 41 reference cites. To obtain a complete set of both articles she wrote, see our order form on the last page of this newsletter.
Common ingredient offers AIDS protection
By Maggie Fox, Health and Science Editor
Wed Mar 4, 2009
WASHINGTON (Reuters) – A cheap ingredient used in ice cream, cosmetics and found in breast milk helps protect monkeys against infection with a virus similar to AIDS and might work to protect women against the virus, researchers reported on Wednesday.
The compound, called glycerol monolaurate, or GML, appears to stop inflammation and helps keep away the cells the AIDS virus usually infects, the researchers said.
While it does not provide 100 percent protection, it might greatly reduce a woman's risk of being infected, and she could use it privately and without hurting her chances of pregnancy, the researchers reported in the journal Nature.
And it costs pennies a dose, Ashley Haase and Pat Schlievert of the University of Minnesota reported.
"For years, people have used the compound as an emulsifying agent in a variety of foods ... it is in breast milk," Schlievert told reporters in a telephone briefing.
GML is being considered as an additive to tampons because it interferes with bacteria, particularly those that can cause a potentially fatal infection called toxic shock syndrome.
If it can be shown to work safely in women, GML might provide the first easy route to a microbicide -- a gel or a cream that women could use vaginally to protect themselves from infection with the human immunodeficiency virus, or HIV, which causes AIDS.
HIV infects 33 million people globally and has killed 25 million. It is transmitted sexually, in blood and breast milk. In Africa, it is most commonly passed during heterosexual contact.
AIDS experts say many victims are married women whose husbands will not use condoms and who are often trying to have children. They need a safe and private way to protect themselves.
A microbicide (pronounced my-CROW-buh-side) might also protect men who have sex with men.
Haase and Schlievert's team tested GML, carried in KY jelly, in macaque monkeys. They put the gel into the vaginas of the monkeys and then applied SIV, a monkey version of HIV.
Four out of five monkeys never became infected and tests showed GML affected the immune response.
HIV is particularly hard to fight because it infects the very immune cells the body uses to attack a virus. When HIV infects an area such as the vagina, the CD4 T-cells rush to defend against it. The body sends out signaling chemicals called cytokines to call in more T-cells.
HIV can then infect them all and spread through the body.
GML appears to stop the cytokine call for help and stops so many T-cells from rushing to the area, Haase and Schlievert said. This in turn reduces the opportunity for HIV to take hold.
"This result represents a highly encouraging new lead in the search for an effective microbicide to prevent HIV transmission that meets the criteria of safety, affordability and efficacy," they wrote.
Even if it was only 60 percent effective, such a gel could prevent 2.5 million HIV cases over three years, they said.
They said they plan to study their gel in more monkeys for longer periods of time to ensure the gel is not simply delaying infection rather than preventing it.
(Editing by Will Dunham)Copyright © 2009 Reuters Limited.